
Overview
Agilent Q4 fiscal revenue grows 9.4%, beating analyst expectations
Adjusted net income for Q4 slightly beats analyst expectations
Company provides optimistic FY26 guidance, expecting revenue growth of 5% to 7%
Outlook
Agilent expects FY26 revenue between $7.3 bln and $7.4 bln
FY26 non-GAAP EPS expected between $5.86 and $6.00
Q1 FY26 revenue guidance between $1.79 bln and $1.82 bln
Result Drivers
LIFE SCIENCES GROWTH - Life Sciences and Diagnostics Markets Group reported 15% revenue growth, driven by strong demand
OPERATIONAL EFFICIENCIES - Expanded Ignite Operating System enhanced operating efficiencies, fueling innovation and commercial execution
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $1.86 bln | $1.83 bln (12 Analysts) |
Q4 EPS |
| $1.53 |
|
Q4 Adjusted Net Income | Slight Beat* | $452 mln | $449.42 mln (11 Analysts) |
Q4 Net Income |
| $434 mln |
|
Q4 Pretax Profit |
| $442 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Agilent Technologies Inc is $150.00, about 0.8% below its November 21 closing price of $151.25
Press Release: ID:nBw6q480Ba
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.